Literature DB >> 18154909

Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors.

Kevin R Krull1, Pim Brouwers, Neelam Jain, Linna Zhang, Lisa Bomgaars, ZoAnn Dreyer, Donald Mahoney, Sarah Bottomley, M Fatih Okcu.   

Abstract

OBJECTIVE: To test the hypothesis that 5,10-methylenetetrahydroreductase (MTHFR) polymorphisms can partially explain the individual variation in developing attention-deficit/hyperactivity disorder (ADHD) after acute lymphoblastic leukemia (ALL) therapy. STUDY
DESIGN: Parents of 48 survivors of childhood ALL completed a clinical diagnostic process to identify subtypes of ADHD. Genotyping was performed with peripheral blood DNA for MTHFR (C677T and A1298C) polymorphisms.
RESULTS: Eleven of the 48 patients (22.9%) had scores consistent with the inattentive symptoms of ADHD. Patients with genotypes related to lower folate levels (11 out of 39; 39.2%) were more likely to have ADHD. The A1298C genotype appeared to be the predominant linkage to the inattentive symptoms, leading to a 7.4-fold increase in diagnosis, compared with a 1.3-fold increase for the C677T genotype. Age at diagnosis and sex were not associated with inattentiveness.
CONCLUSIONS: Preliminary data imply a strong relationship between MTHFR polymorphisms and the inattentive symptoms of ADHD in survivors of childhood ALL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18154909     DOI: 10.1016/j.jpeds.2007.05.047

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  37 in total

1.  Symptoms of attention-deficit/hyperactivity disorder in long-term survivors of childhood leukemia.

Authors:  Kevin R Krull; Raja B Khan; Kirsten K Ness; Davonna Ledet; Liang Zhu; Ching-Hon Pui; Scott C Howard; Deo Kumar Srivastava; Noah D Sabin; Melissa M Hudson; E Brannon Morris
Journal:  Pediatr Blood Cancer       Date:  2011-01-28       Impact factor: 3.167

Review 2.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

3.  Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial.

Authors:  Heather M Conklin; Susan Helton; Jason Ashford; Raymond K Mulhern; Wilburn E Reddick; Ronald Brown; Melanie Bonner; Bruce W Jasper; Shengjie Wu; Xiaoping Xiong; Raja B Khan
Journal:  J Pediatr Psychol       Date:  2009-05-22

4.  Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia.

Authors:  Kevin R Krull; Deepa Bhojwani; Heather M Conklin; Deqing Pei; Cheng Cheng; Wilburn E Reddick; John T Sandlund; Ching-Hon Pui
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

5.  Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years post-diagnosis.

Authors:  Deborah P Waber; Jennifer Turek Queally; Lori Catania; Philippe Robaey; Ivonne Romero; Heather Adams; Cheryl Alyman; Christine Jandet-Brunet; Stephen E Sallan; Lewis B Silverman
Journal:  Pediatr Blood Cancer       Date:  2011-06-30       Impact factor: 3.167

Review 6.  Genetic Modulation of Neurocognitive Development in Cancer Patients throughout the Lifespan: a Systematic Review.

Authors:  Charlotte Sleurs; Aline Madoe; Lieven Lagae; Sandra Jacobs; Sabine Deprez; Jurgen Lemiere; Anne Uyttebroeck
Journal:  Neuropsychol Rev       Date:  2019-03-30       Impact factor: 7.444

7.  Association of Attention Deficit Disorder With Bedside Anti-saccades in Survivors of Childhood Leukemia.

Authors:  Raja B Khan; Melissa M Hudson; Kirsten K Ness; Zhu Liang; Deokumar Srivastava; Kevin R Krull
Journal:  J Child Neurol       Date:  2015-04-26       Impact factor: 1.987

8.  The impact of attention on social functioning in survivors of pediatric acute lymphoblastic leukemia and brain tumors.

Authors:  Katherine H Moyer; Victoria W Willard; Alan M Gross; Kelli L Netson; Jason M Ashford; Lisa S Kahalley; Shengjie Wu; Xiaoping Xiong; Heather M Conklin
Journal:  Pediatr Blood Cancer       Date:  2012-07-27       Impact factor: 3.167

Review 9.  Cancer pharmacogenomics in children: research initiatives and progress to date.

Authors:  Shahrad Rod Rassekh; Colin J D Ross; Bruce C Carleton; Michael R Hayden
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

Review 10.  A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk.

Authors:  Muzeyyen Izmirli
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.